{
    "clinical_study": {
        "@rank": "153",
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on April 09, 2020",
            "link_text": "Link to the current ClinicalTrials.gov record.",
            "url": "https://clinicaltrials.gov/show/NCT04338698"
        },
        "id_info": {
            "org_study_id": "12(06)/2016-Coord",
            "nct_id": "NCT04338698"
        },
        "brief_title": "Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT",
        "acronym": "PROTECT",
        "official_title": "Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment",
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shehnoor Azhar",
                "agency_class": "Other"
            },
            "collaborator": {
                "agency": "Federal Task Force on Science & Technology notified by Government of Pakistan",
                "agency_class": "Other"
            }
        },
        "source": "University of Health Sciences Lahore",
        "oversight_info": {
            "has_dmc": "Yes",
            "is_fda_regulated_drug": "No",
            "is_fda_regulated_device": "No"
        },
        "brief_summary": {
            "textblock": "To evaluate the effectiveness of Hydroxychloroquine Phosphate/Sulfate (200 mg orally 8hr\n      thrice a day for 5 days) vs oseltamivir (75 mg orally twice a day for 5 days) vs Azithromycin\n      (500 mg orally daily on day 1, followed by 250 mg orally twice a day on days 2-5) alone and\n      in combination (in all seven groups), in clearing the coronavirus nucleic acid from throat\n      and nasal swab and in bringing about clinical improvement on day 7 of follow-up (primary\n      outcomes)."
        },
        "detailed_description": {
            "textblock": "A scientific taskforce notified by the Ministry of Science and Technology of the Government\n      of Pakistan will oversee a comprehensive cohort study. Within this cohort, a multicenter,\n      adaptive, randomized controlled trial will evaluate, among eligible SARS-Cov-2 (COVID-19)\n      infected patients receiving standard supportive care who consent to randomization following a\n      new diagnosis in Pakistan, if Hydroxychloroquine Phosphate/Sulfate alone (control\n      intervention) vs a series of alternatives (comparator interventions) including Oseltamivir\n      and Azithromycin alone and in combination with Hydroxychloroquine Phosphate/Sulfate is\n      effective in clearing the coronavirus and improving the clinical course of the disease. Those\n      not consenting to randomization will be followed up for outcomes of SARS-Cov-2 infection with\n      supportive care only. Findings of this study are expected to inform clinical care and public\n      health protocols and policies for management of SARS-Cov-2."
        },
        "overall_status": "Not yet recruiting",
        "start_date": {
            "@type": "Anticipated",
            "#text": "April 7, 2020"
        },
        "completion_date": {
            "@type": "Anticipated",
            "#text": "November 30, 2020"
        },
        "primary_completion_date": {
            "@type": "Anticipated",
            "#text": "September 1, 2020"
        },
        "phase": "Phase 3",
        "study_type": "Interventional",
        "has_expanded_access": "No",
        "study_design_info": {
            "allocation": "Randomized",
            "intervention_model": "Parallel Assignment",
            "intervention_model_description": "Adaptive design (sample size given below is indicative)",
            "primary_purpose": "Treatment",
            "masking": "Double (Investigator, Outcomes Assessor)"
        },
        "primary_outcome": [
            {
                "measure": "Laboratory Result",
                "time_frame": "Day 07 on follow-up",
                "description": "The laboratory-based primary outcome will be turning test negative for COVID-19 on RT-qPCR calculated as viral load of < 150 i.u"
            },
            {
                "measure": "Clinical Outcome",
                "time_frame": "Day 07 on follow-up",
                "description": "The clinical primary outcome will improvement of two points on a seven-category ordinal scale"
            }
        ],
        "number_of_arms": "8",
        "enrollment": {
            "@type": "Anticipated",
            "#text": "500"
        },
        "condition": "COVID 19",
        "arm_group": [
            {
                "arm_group_label": "Control Intervention",
                "arm_group_type": "Active Comparator",
                "description": "Hydroxychloroquine"
            },
            {
                "arm_group_label": "Comparator 1",
                "arm_group_type": "Experimental",
                "description": "Azithromycin"
            },
            {
                "arm_group_label": "Comparator 2",
                "arm_group_type": "Experimental",
                "description": "Oseltamivir"
            },
            {
                "arm_group_label": "Comparator 3",
                "arm_group_type": "Experimental",
                "description": "Hydroxychloroquine + Azithromycin"
            },
            {
                "arm_group_label": "Comparator 4",
                "arm_group_type": "Experimental",
                "description": "Hydroxychloroquine + Oseltamivir"
            },
            {
                "arm_group_label": "Comparator 5",
                "arm_group_type": "Experimental",
                "description": "Oseltamivir + Azithromycin"
            },
            {
                "arm_group_label": "Comparator 6",
                "arm_group_type": "Experimental",
                "description": "Hydroxyquinine + Oseltamivir + Azithromycin"
            },
            {
                "arm_group_label": "Observational Cohort",
                "arm_group_type": "No Intervention",
                "description": "Non-consenting to randomization"
            }
        ],
        "intervention": [
            {
                "intervention_type": "Drug",
                "intervention_name": "Hydroxychloroquine",
                "description": "Hydroxychloroquine Phosphate/Sulfate (200 mg orally thrice a day for 5 days)",
                "arm_group_label": [
                    "Comparator 3",
                    "Comparator 4",
                    "Comparator 6",
                    "Control Intervention"
                ]
            },
            {
                "intervention_type": "Drug",
                "intervention_name": "Oseltamivir",
                "description": "Oseltamivir (75 mg orally twice a day for 5 days)",
                "arm_group_label": [
                    "Comparator 2",
                    "Comparator 4",
                    "Comparator 5",
                    "Comparator 6"
                ]
            },
            {
                "intervention_type": "Drug",
                "intervention_name": "Azithromycin",
                "description": "Azithromycin (500 mg orally once a day on day 1, followed by 250 mg orally daily on days 2-5)",
                "arm_group_label": [
                    "Comparator 1",
                    "Comparator 3",
                    "Comparator 5",
                    "Comparator 6"
                ]
            }
        ],
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Confirmed SARS-CoV-2 (COVID-19) infection by a positive test result\n\n          2. Either gender\n\n          3. Symptomatic for example fever, dry Cough, difficulty to breathe\n\n        Exclusion Criteria:\n\n          1. Confirmed absence of SARS-CoV-2 (COVID-19) infection by a negative test result\n\n          2. Have chronic conditions such as heart disease, liver and kidney failure\n\n          3. Pregnant or currently lactating\n\n          4. Immunocompromise and/or systemic disease(s)\n\n          5. On other antiviral drugs\n\n          6. History of allergy to any of the drugs to be administered in this study"
            },
            "gender": "All",
            "minimum_age": "18 Years",
            "maximum_age": "N/A",
            "healthy_volunteers": "No"
        },
        "overall_official": {
            "last_name": "Javed Akram, FRCP",
            "role": "Principal Investigator",
            "affiliation": "University of Health Sciences Lahore"
        },
        "overall_contact": {
            "last_name": "Shehnoor Azhar, MPH",
            "phone": "+92 321 4090221",
            "email": "shehnoor.azhar@gmail.com"
        },
        "verification_date": "April 2020",
        "study_first_submitted": "April 4, 2020",
        "study_first_submitted_qc": "April 4, 2020",
        "study_first_posted": {
            "@type": "Actual",
            "#text": "April 8, 2020"
        },
        "last_update_submitted": "April 4, 2020",
        "last_update_submitted_qc": "April 4, 2020",
        "last_update_posted": {
            "@type": "Actual",
            "#text": "April 8, 2020"
        },
        "responsible_party": {
            "responsible_party_type": "Sponsor-Investigator",
            "investigator_affiliation": "University of Health Sciences Lahore",
            "investigator_full_name": "Shehnoor Azhar",
            "investigator_title": "Study Coordinator"
        },
        "intervention_browse": {
            "mesh_term": [
                "Hydroxychloroquine",
                "Oseltamivir"
            ]
        },
        "patient_data": {
            "sharing_ipd": "Yes",
            "ipd_description": "On completion of study, investigators are open to participation in planned IPD projects with a prospective registration, subject to appropriate approvals"
        }
    }
}